IN2014MN02675A - - Google Patents

Info

Publication number
IN2014MN02675A
IN2014MN02675A IN2675MUN2014A IN2014MN02675A IN 2014MN02675 A IN2014MN02675 A IN 2014MN02675A IN 2675MUN2014 A IN2675MUN2014 A IN 2675MUN2014A IN 2014MN02675 A IN2014MN02675 A IN 2014MN02675A
Authority
IN
India
Prior art keywords
composition
treatment
pathologies
aim
guaranteed
Prior art date
Application number
Other languages
English (en)
Inventor
Aldecoa Eduardo Anitua
Original Assignee
Biotechnology Inst I Mas D Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49111229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN02675(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotechnology Inst I Mas D Sl filed Critical Biotechnology Inst I Mas D Sl
Publication of IN2014MN02675A publication Critical patent/IN2014MN02675A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IN2675MUN2014 2012-08-09 2013-07-19 IN2014MN02675A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201200810A ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
PCT/ES2013/000176 WO2014023860A1 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas

Publications (1)

Publication Number Publication Date
IN2014MN02675A true IN2014MN02675A (cg-RX-API-DMAC7.html) 2015-08-28

Family

ID=49111229

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2675MUN2014 IN2014MN02675A (cg-RX-API-DMAC7.html) 2012-08-09 2013-07-19

Country Status (17)

Country Link
US (2) US20140044795A1 (cg-RX-API-DMAC7.html)
EP (1) EP2883569B1 (cg-RX-API-DMAC7.html)
JP (1) JP6339568B2 (cg-RX-API-DMAC7.html)
KR (1) KR102149162B1 (cg-RX-API-DMAC7.html)
CN (1) CN104519961A (cg-RX-API-DMAC7.html)
AR (1) AR092086A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015002760A2 (cg-RX-API-DMAC7.html)
CA (1) CA2881075A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014003510A1 (cg-RX-API-DMAC7.html)
CO (1) CO7170177A2 (cg-RX-API-DMAC7.html)
ES (2) ES2442242B1 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02675A (cg-RX-API-DMAC7.html)
MX (1) MX357828B (cg-RX-API-DMAC7.html)
PE (1) PE20150616A1 (cg-RX-API-DMAC7.html)
RU (1) RU2696497C2 (cg-RX-API-DMAC7.html)
TW (1) TWI649084B (cg-RX-API-DMAC7.html)
WO (1) WO2014023860A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033813A1 (en) * 1998-12-09 2000-06-15 Chiron Corporation Administration of neurotrophic agents to the central nervous system
AR022333A1 (es) 1999-01-26 2002-09-04 Anitua Aldecoa Eduardo Regenerador de tejido oseo
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
ES2221770B2 (es) 2002-04-19 2006-07-16 Eduardo Anitua Aldecoa Metodo de preparacion de un compuesto para la regeneracion de tejidos.
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
JP5276982B2 (ja) * 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
EP2152240A4 (en) * 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
ES2333498B1 (es) * 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
CA2699411A1 (en) * 2007-09-14 2009-03-19 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
PT2430977T (pt) * 2009-05-14 2020-03-26 Biotechnology Inst I Mas D Sl Método para a preparação de pelo menos um composto do sangue, e dispositivo de amostragem para utilização na realização do referido método
KR101114712B1 (ko) * 2009-10-23 2012-02-29 세원셀론텍(주) 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(prp)을 활성화하여 조직재생을 유도하는 조성물의 제조방법
ES2369945B1 (es) * 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.

Also Published As

Publication number Publication date
US20160184360A1 (en) 2016-06-30
JP2015524464A (ja) 2015-08-24
MX2015001677A (es) 2015-04-10
TW201408310A (zh) 2014-03-01
CL2014003510A1 (es) 2015-05-04
KR20150040860A (ko) 2015-04-15
ES2662385T3 (es) 2018-04-06
CN104519961A (zh) 2015-04-15
RU2015104076A (ru) 2016-09-27
KR102149162B1 (ko) 2020-08-31
MX357828B (es) 2018-07-25
WO2014023860A1 (es) 2014-02-13
TWI649084B (zh) 2019-02-01
RU2696497C2 (ru) 2019-08-02
EP2883569A1 (en) 2015-06-17
EP2883569B1 (en) 2017-12-20
JP6339568B2 (ja) 2018-06-06
CA2881075A1 (en) 2014-02-13
PE20150616A1 (es) 2015-05-25
BR112015002760A2 (pt) 2020-04-22
CO7170177A2 (es) 2015-01-28
US20140044795A1 (en) 2014-02-13
ES2442242B1 (es) 2014-11-25
ES2442242A1 (es) 2014-02-10
AR092086A1 (es) 2015-03-25

Similar Documents

Publication Publication Date Title
BR112015012238A2 (cg-RX-API-DMAC7.html)
BR112014017635A2 (cg-RX-API-DMAC7.html)
BR112014017614A2 (cg-RX-API-DMAC7.html)
BR112014018171A2 (cg-RX-API-DMAC7.html)
BR112014017625A2 (cg-RX-API-DMAC7.html)
BR112014017659A2 (cg-RX-API-DMAC7.html)
AR092201A1 (cg-RX-API-DMAC7.html)
BR112014024270A2 (cg-RX-API-DMAC7.html)
BR112013027865A2 (cg-RX-API-DMAC7.html)
BR112014017644A2 (cg-RX-API-DMAC7.html)
BR112014017634A2 (cg-RX-API-DMAC7.html)
BR112014017647A2 (cg-RX-API-DMAC7.html)
BR112014017627A2 (cg-RX-API-DMAC7.html)
BR112014017623A2 (cg-RX-API-DMAC7.html)
BR112014017630A2 (cg-RX-API-DMAC7.html)
BR112014017621A2 (cg-RX-API-DMAC7.html)
BR112014017631A2 (cg-RX-API-DMAC7.html)
BR112014017622A2 (cg-RX-API-DMAC7.html)
BR112015014744A2 (cg-RX-API-DMAC7.html)
BR112014017671A2 (cg-RX-API-DMAC7.html)
BR112014017589A2 (cg-RX-API-DMAC7.html)
BR112014017600A2 (cg-RX-API-DMAC7.html)
BR112014017636A2 (cg-RX-API-DMAC7.html)
BR112014017667A2 (cg-RX-API-DMAC7.html)
BR112014017948A2 (cg-RX-API-DMAC7.html)